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Abstract
Background: Recent reports using metabolism regulating drugs showed that nutrient deprivation was an efficient
tool to suppress cancer progression. In addition, autophagy control is emerging to prevent cancer cell survival.
Autophagy breaks down the unnecessary cytoplasmic components into anabolic units and energy sources, which
are the most important sources for making the ATP that maintains homeostasis in cancer cell growth and survival.
Therefore, the glucose analog 2-deoxyglucose (2DG) has been used as an anticancer reagent due to its inhibition of
glycolysis.
Methods: Prostate cancer cells (PC3) were treated with 2DG for 6 h or 48 h to analyze the changing of cell cycle
and autophagic flux. Rapamycin and LC3B overexpressing vectors were administered to PC3 cells for autophagy
induction and chloroquine and shBeclin1 plasmid were used to inhibit autophagy in PC3 cells to analyze PC3 cells
growth and survival. The samples for western blotting were prepared in each culture condition to confirm the
expression level of autophagy related and regulating proteins.
Results: We demonstrated that 2DG inhibits PC3 cells growth and had discriminating effects on autophagy
regulation based on the different time period of 2DG treatment to control cell survival. Short-term treatment of
2DG induced autophagic flux, which increased microtubule associated protein 1 light chain 3B (LC3B) conversion
rates and reduced p62 levels. However, 2DG induced autophagic flux is remarkably reduced over an extended time
period of 2DG treatment for 48 h despite autophagy inducing internal signaling being maintained. The relationship
between cell growth and autophagy was proved. Increased autophagic flux by rapamycin or LC3B overexpression
powerfully reduced cell growth, while autophagy inhibition with shBeclin1 plasmid or chloroquine had no
significant effect on regulating cell growth.
Conclusion: Given these results, maintaining increased autophagic flux was more effective at inhibiting cancer cell
progression than inhibition of autophagic flux, which is necessary for the survival of PC3 cells. Autophagic flux
should be tightly regulated to maintain metabolic homeostasis for cancer cell growth and survival in PC3 cells and
is a suitable target for cancer therapy.
Background
Advances in surgery, hormone therapy, and chemo-
therapy have improved advanced prostate cancer
treatments. however, these approaches are limited due
to prostate cancer therapy resistance. Thus, there is a
critical need to develop treatments against new
cellular targets. Recently, regulation of metabolism in
cancer therapy is emerging, because rapidly growing
cells need plenty of the energy, nutrients, and build-
ing blocks that are required to maintain cell survival
and proliferation [1–3]. Aggressive cancers consume
abundant glucose to produce ATP using glycolysis, to
promote the pentose phosphate pathway (PPP) to de-
crease oxidative stress, and to make many kinds of
biomaterials [4–7]. One promising metabolic-control
is chemotherapy using 2-deoxyglucose (2DG), which is a
well-known glycolysis inhibitor [8, 9]. 2DG inhibits
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hexokinase, the rate-limiting enzyme of glycolysis,
leading to depleted ATP, antioxidants, and glycolysis
intermediates needed for cell survival and mainten-
ance, thereby causing cell growth arrest and death
[10–12]. Coincidently, autophagy induction rises in
response to intracellular starved conditions and ER
stress by 2DG as a cell survival process [3, 13].
Autophagy has an important role in the catabolic
pathways that support intracellular energy sources and
building blocks and clears cytotoxins to sustain homeo-
stasis by degrading unfolded or aggregated protein and
damaged cytoplasmic components with lysosomal prote-
ases [14]. In cancer, functioning autophagy is crucial to
survival and growth because rapidly proliferating cancer
cells need vast energy and biomass to make new proteins,
lipids, and intracellular components, and must remove
protein aggregates, abnormal cytoplasmic compartments,
excess reactive oxygen species, and lipid droplets to main-
tain the homeostasis that is produced during the develop-
ment of cancer [15, 16]. These helpful functions of
autophagy produce pro-survival effects in cancer develop-
ment and increase resistance to chemotherapy [17, 18].
Therefore, recent reports tried to administer combination
chemotherapy of both an anticancer drug and an autoph-
agy inhibitor to block the pro-survival function of autoph-
agy and showed a synergistic anticancer effect [19–22].
However, some groups demonstrated that autophagy con-
tributed to the pro-death function rather than the pro-
survival role. Excessive autophagy activation leads to cell
death and depends on the cell types and culture environ-
ments. It is termed “autophagic cell death,” and arises
from unlimited degradation of cytoplasmic components
[23–26]. The double-edged sword effects of autophagy on
cell survival or death are controversial [27, 28].
To determine whether autophagy is harmful or helpful
for PC3 cells or LNcaP cells survival and growth under
nutrient depleted conditions by 2DG, we investigated
2DG’s effect on autophagy regulation in PC3 cells and
LNcaP cells, and proved that 2DG significantly sup-
pressed both cells’ growth and promoted intense autoph-
agic flux. Autophagic flux was differentially regulated
depending on the exposure time of 2DG. Especially, in-
creased autophagic flux significantly suppressed PC3




Human prostate cancer cell line PC3 and human em-
bryonic kidney cell line 293 T were purchased from
American Type Culture Collection (ATCC, Manassas,
VA) and maintained in Dulbecco’s modified Eagle
medium (Gibco, Grand Island, NY, USA) with
penicillin-streptomycin (100 U/mL; Gibco) and 10 %
fetal bovine serum (Gibco) in a humidified atmos-
phere of 95 % air and 5 % CO2 at 37 °C.
Cell growth assay
PC3 cells were seeded into 96-well plates (5 × 103 cells
per well) and incubated overnight. The next day the cul-
ture medium in each well was changed with a different
concentration of 2DG containing culture medium and
cultured for 3 days. After 2DG treatment, the PC3 cells
on the culture plate were counted or we performed an
MTT assay. Briefly, PC3 cells on the culture plate were
treated with 0.5 mg/mL Thiazolyl blue tetrazolium
bromide (MTT, Sigma, Louis, MO, USA) for 4 h and
washed with phosphate-buffered saline (PBS). After-
wards, the plates were drained upside down on a paper
towel and then solubilized with DMSO. Each well was
measured using the optical density at 570 nm.
Confocal microscopy imaging
PC3 cells were seeded on glass-bottomed cell culture
dishes (NEST Biotechnology, Shanghai, China) and incu-
bated for 24 h. The culture medium was then changed
to 2DG containing culture medium and incubated for
48 h. Cells were fixed with 10 % paraformaldehyde for
30 min and washed three times with PBS. To increase
permeabilization, cells were incubated in 0.25 % Triton
X-100-containing PBS for 10 min. After washing the
cells with a PBS blocking solution (3 % bovine serum al-
bumin, 0.25 % Triton X-100 in PBS), cells were treated
for 30 min followed by incubation overnight at 4 °C with
diluted primary antibody against microtubule-associated
protein 1 light chain-3B (LC3B; 1:200, Cell Signaling
Technology, Danvers, MA, USA) or p62 (1:200, Santa
Cruz Biotechnology, Dallas, TX, USA) in blocking solu-
tion. The next day, the cells were washed three times
with PBS then incubated with diluted secondary anti-
body (1:500, Invitrogen, Oregon, USA) in blocking solu-
tion for 1 h. After washing the cells in PBS, Hoechst
33258 was used to stain the nucleus. The cells were ana-
lyzed using a Carl Zeiss LMS710 confocal microscope
(Carl Zeiss, Gottingen, Germany).
Fluorescence-activated cell sorting (FACS) analysis
Chemically pre-treated PC3 cells were trypsinized and
harvested. Cells were fixed with 70 % ethanol for 1 h on
ice and collected for permeabilization of the cell with
0.25 % Triton X-100. After centrifugation to collect the
cells, we removed the supernatant and resuspended the
cells with 10 μg/mL RNase and 20 μg/mL propidium
iodide-containing PBS for 30 min at room temperature.
The DNA content of the cells was measured using an
LSRII flow cytometer (BD Bioscience, CA, USA).
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Overexpression of LC3B
PC3 cells were seeded into 6-well plates (1 × 104 cells
per well) and incubated overnight. LC3B or control gene
plasmids were purchased from Addgene (MA, USA).
Two mg of each plasmid was transfected into cultured
PC3 cells using 0.2 μL/well Lipofectamine2000 (Invitro-
gen) according to the manufacturer’s protocols. Then
LC3B-overexpressing cells were selected in culture
medium containing 200 μg/mL Genectin (Invitrogen).
Knockdown of autophagy related genes
293 T cells were seeded into 60 mm culture dishes
(1 × 105 cells) and incubated overnight. Lenti-viral
plasmid of Beclin1 or non-targeting shRNA plasmids
(1–4 μg; Sigma) were transfected into cultured 293 T
cells using 20 μL/well Lipofectamine2000 according to
the manufacturer’s protocols to produce virus parti-
cles. After 2 days, the culture medium of plasmid
transfected 293 T cells was collected and transferred
to overnight cultured PC3 cells (1 × 105 cells per
100 mm dish) for virus infection. We removed the viral
particle containing medium and replaced it with normal
culture medium followed by cell incubation for 2 days.
Afterwards, Beclin1 or non-targeting shRNA plasmid in-
fected cells were selected in puromycin containing culture
medium (2 μg/mL, Invitrogen).
Western blot analysis
Cells were washed with PBS and lysed with 1 % sodium
dodecyl sulfate (SDS) lysis buffer (60 mM Tris–HCl,
pH 6.8, 1 % SDS) with protease inhibitor cocktail
(Roche, Mannheim, Germany). Equal amounts of total
protein from each sample were separated by SDS-
polyacrylamide gel electrophoresis on 8 % or 12 % gels,
and transferred onto polyvinylidene difluoride mem-
branes (Millipore, Billerica MA, USA). Following incuba-
tion with primary antibodies against mammalian target
of rapamycin (mTOR; 2972), phospho-mTOR (2448),
protein kinase B (AKT; 9272), phospho-AKT (9271),
AMP-activated protein kinase (AMPK; 2603), phospho-
AMPK (2535), cell cycle-regulation antibody (9932,
9870; Cell Signaling Technology, Danvers, MA), p62
(SC28359; Santa Cruz Biotechnology, Dallas, Texas,
USA), LC3B (L7543), and actin (A1978; Sigma), mem-
branes were incubated with goat anti-rabbit (sc2004) or
anti-mouse (sc2005) IgG horseradish peroxidase (Santa
Cruz Biotechnology) as the secondary antibody. Labeled,
specific protein bands were visualized using the ECL Kit
(Thermo Scientific, Rockford, IL, USA).
Chemicals
CQ (Sigma), a late-phase inhibitor of autophagy, was used
at a final concentration of 20 μM for 2 h. Rapamycin
(Sigma), blocker of the mTOR signaling pathway, was
used as activator of autophagy at various concentrations.
Statistical analysis
Each experiment was carried out in triplicate, and quan-
titative data were expressed as the mean ± S.D. Statistical
analysis was conducted using the GraphPad Prism Soft-
ware (San Diego, Calif., USA).
Result
2DG regulates cell growth and autophagy
The glycolysis inhibitor 2DG induces intracellular energy
deficiency, which causes cell growth suppression and in-
duction of autophagy. We investigated whether 2DG has
these effects on PC3 prostate cancer cells. The growth of
PC3 cells was significantly inhibited by 2DG in a dose
dependent manner, and the suppression effects of 2DG
were strongly observed even at a 5 mM 2DG concentra-
tion (Figure 1a). Autophagy was inhibited by 2DG. This
was confirmed by LC3B expression levels and highly ac-
cumulated autophagy substrate p62 levels in the western
blots (Fig. 1b) and confocal imaging (Fig. 1c). As shown
in Fig. 1b and c, the level of accumulated p62 gradually
increased with higher 2DG concentration. These effects
of 2DG were similarly observed in LNCaP prostate can-
cer cells (Additional file 1: Figure S1A and S1B). 2DG
inhibits cell growth and autophagy.
2DG controls the cell cycle of PC3 cells
We wondered how 2DG controls the growth of PC3
cells. We observed the changes in cell cycle based on
2DG concentration and treatment time. There were no
significant changes in cell cycle with a short-term treat-
ment of 2DG. However, long-term treatment of 2DG
strongly increased the G0/G1 phase and decreased the S
phase in 5 mM 2DG treated PC3 cells. Interestingly,
higher concentrations of 2DG remarkably decreased the
S phase and increased the G2 phase rather than changing
the G0/G1 phase (Fig. 2a). To check the relationship be-
tween the cell cycle and autophagy, we administered
chemical regulators of autophagy using the autophagy in-
hibitor CQ or the autophagy inducer rapamycin for 6 h in
PC3 cells. Both regulators showed no statistically signifi-
cant effects on cell cycle arrest, and only rapamycin in-
creased G2 phase arrest. These results were confirmed
with western blot. The expression level of G0/G1 or G2/
M related markers, cyclinD1, cyclin dependent kinase 4
(CDK4), and cell division control protein 2 (cdc2) was de-
creased, but CDK6 and cyclin dependent kinase inhibitor
2b (p15) were not changed by 2DG, which was remarkably
shown with the 2DG treatment condition for 48 h
(Fig. 2b). LNCaP cells also showed cell cycle arrest that
the expression level of cyclinD1, p15 and cdc2 were sig-
nificantly decreased but the expression level of CDK4 was
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not changed (Additional file 1: Figure S1C). Taken to-
gether, 2DG induced G0/G1 arrest at the early phase and
G2/M arrest at the late phase of autophagy induction, in-
ducing cell cycle arrest.
Autophagy is differentially regulated by 2DG
We observed that 2DG significant inhibited PC3 cell
growth and blocked autophagy, but cell cycle arrest was
increased by autophagy induction. Because of these in-
teresting results, we checked the relationship between
autophagy regulation and 2DG. We measured the au-
tophagic flux with a lysosomal protease inhibitor, CQ,
which blocks proteolysis in the lysosome and leads to
the accumulation of LC3B and p62. We analyzed the
amount of accumulated LC3B and p62, which indicates
autophagic flux. Western blotting showed that the accu-
mulated LC3B and p62 levels with CQ treatment for 2 h
were strongly increased by short-term treatment with
2DG for 6 h compared to the control treatment condition
and were enhanced further with higher concentrations.
Fig. 1 2-deoxyglucose inhibits PC3 prostate cancer cell growth and inhibits autophagy. PC3 cells were incubated with different concentrations of 2-
deoxyglucose (2DG). a Cell growth rate was measured by counting the cell numbers at the indicated time points for 3 days. Data are represented as
means ± SD. ***P < 0.001, control versus 5 mM 2DG; ***P < 0.001, control versus 10 mM 2DG; ***P < 0.001, control versus 20 mM 2DG. (b) After 2DG
treatment for 48 h, autophagy levels were detected using western blotting analysis. p62 was used as an autophagy substrate and LC3B showed
autophagy levels. (c) The level of autophagy was confirmed with confocal microscopy. Blue, nucleus; Green, LC3B; Red, p62
Fig. 2 Long-term exposure to 2DG enhances cell cycle arrest. PC3 cells were treated with 2DG for a short time (6 h) or long time (48 h). CQ was
used as an autophagy inhibitor at a final concentration of 20 μM for 2 h. Rapamycin was used as an autophagy inducer at 100 nM for 6 h. a After
2DG treatment, each cell was collected for FACS analysis. Cells were stained with iodine for 5 min and analyzed for the amount of DNA content.
Each DNA content rate is expressed as G1, S, and G2 phase. Data are represented as the means ± SD. *P < 0.05, **P < 0.01, **P < 0.001. (b) Expression
levels of cell cycle related genes were observed using western blotting analysis
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However, there were no differences seen with long-term
treatment of 2DG for 48 h, either with CQ or alone. CQ
did not affect p62 and LC3B accumulation (Fig. 3a). As
shown in Fig. 3b, Additional file 2: Figure S2A and S2B,
2DG noticeably increased autophagic flux at the early
phase, but significantly inhibited autophagic flux in PC3
cells and LNCaP cells.
Next, we observed changes in intracellular signal path-
ways related to autophagy regulation. In autophagy regu-
lation, mTOR and AMPK are representative signaling
pathways. mTOR has a negative role by inhibiting unc-
51-like autophagy activating kinase 1 (ULK1) phosphor-
ylation, which prevents autophagy initiation. mTOR is
inhibited by the autophagy inducing chemical rapamy-
cin. In contrast, AMPK has positive role by inhibiting
the mTOR pathway [29]. Western blotting results showed
that the phosphorylated level of mTOR/AKT was de-
creased in a time-dependent manner, but phosphorylated
level of AMPK was strongly increased by treatment with
2DG. The phosphorylated level of AMPK was increased
in LNCaP cells by 2DG. These changes of intracellular sig-
naling pathways were positive for autophagy induction
and continued for 48 h of 2DG treatment (Fig. 3c and
Additional file 2: Figure S2C).
These results mean that autophagic flux was differen-
tially regulated over the time period of 2DG treatment.
Increased autophagic flux in the early phase of 2DG
treatment was eventually inhibited by the expanded time
of 2DG treatment, although the autophagy inducing sig-
nal was constantly transduced.
Autophagic flux regulates cell growth and survival
We investigated whether autophagy regulates the cell
cycle or survival of PC3 cells. To confirm the relation-
ship between autophagy inhibition and cell growth, we
knocked-down Beclin1, an important component of the
autophagy initiation process. PC3 cells were transfected
with a shBeclin1 or shNon-target (shNT) plasmid.
Fig. 3 Autophagic flux is differentially regulated by exposure time to 2DG. 2DG was administered to PC3 cell, with CQ or alone, to confirm autophagic
flux. a Protein levels of p62 and LC3B in 2DG containing culture medium for the indicated time followed by CQ or no further treatment were
observed with western blotting. L.E. means long exposure. (b) Autophagic flux calculated by the accumulated amount of LC3B with treatment of CQ
autophagy blocker for 2 h. Data are represented as the means ± SD. ***P < 0.001 for both culture conditions. (c) The changes in intracellular signaling
pathway related autophagy regulation were verified for each condition. Phosphorylated levels of mTOR and AKT were checked for whether the
inhibitory signal of autophagy was induced. The AMPK signaling pathway was confirmed as an autophagy activating condition
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Beclin1 knocked-down PC3 cells showed accumulated
p62 levels in normal conditions, but there were no sig-
nificant differences between only Beclin1 knocked-down
culture conditions and 2DG added conditions (Fig. 4a).
In the autophagy-regulating signaling pathways, phos-
phorylated levels of mTOR/AKT between shBeclin1 and
shNT transduced PC3 cells under each condition were
not different. Only the AMPK signaling pathway was in-
tensely activated by the autophagy knockdown in 2DG
treated conditions compared with normal culture condi-
tions (Fig. 4b). This means that autophagy knockdown
was not critical for intracellular signal transduction.
In addition, expression levels of cell cycle regulated
genes were not different in shBeclin1 plasmid trans-
duced PC3 cells than in shNT plasmid bearing PC3 cells
under any condition (Fig. 4c). We investigated whether
autophagy inhibition can suppress PC3 cell growth. PC3
cells were blocked for autophagic flux using the chem-
ical inhibitor CQ (Fig. 5a) or genetic modification with
shRNA plasmids to check cell growth (Fig. 5b). The level
of Beclin1 expression was confirmed with western blot
and undetectable in shBeclin1 plasmid bearing PC3 cells
(Fig. 5b right panel). Under both conditions, PC3 cell
growth was not different between normal conditions and
2DG treated conditions (Fig. 5a and b). LNCaP cells did
not show any growth inhibiting effect by autophagy in-
hibition (Additional file 3: Figure S3A). Although the
CQ concentration was increased, CQ had no effect on
the cell growth of both cells (Fig. 5a and Additional file
3: Figure S3A). After observing no relationship between
autophagy blocking and cell growth, we established an
LC3B overexpressing PC3 cell line to confirm that au-
tophagy activation has an inhibitory effect on cell
growth. The level of LC3B expression was confirmed
with western blot and was strongly increased in LC3B
plasmid bearing PC3 cells. Chemical activation of au-
tophagy with rapamycin strongly inhibited the growth of
PC3 and LNCaP cells in a dose dependent manner and
showed a noticeable effect even at very low concentra-
tions of 1 nM (Fig. 5c and Additional file 3: Figure S3B).
Autophagy activation by LC3B overexpression very in-
tensely inhibited PC3 cell growth similar to 2DG treated
conditions. Interestingly, we observed that the survival
of LC3B overexpressing PC3 cells decreased up to 20 %
Fig. 4 Knockdown of Beclin1 is not effective at regulating the cell cycle. The samples for western blotting were prepared in each culture condition.
Afterwards, a changing autophagy levels, (b) the kinetics of signaling proteins in autophagy regulation, and (c) the expression levels of cell cycle
related genes were checked in both normal and Beclin1 knocked-down PC3 cells using shRNA introduction. shN.T., non-targeting shRNA; shBec1,
shRNA for Beclin1
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with 2DG treatment (Fig. 5d). These results indicate that
cell growth and cell survival are related to autophagy ac-
tivation rather than autophagy inhibition.
Discussion
This study was carried out with the hypothesis that 2DG
controls cell growth and survival through autophagy
regulation. 2DG triggers intracellular energy deficiency
via glycolysis inhibition and increased endoplasmic
reticulum (ER) stress, which induces cell death and ar-
rest [9, 30]. Recent studies reported that genetic or
chemical cancer cell metabolism manipulation, including
2DG treatment, showed remarkable antitumor effects
[31, 32]. Cheong et al. demonstrated that 2DG induced
cell death and showed synergistic effects using metfor-
min co-treatment conditions [33]. Our data proved the
anticancer effects of 2DG in prostate cancer cells by
inhibiting cell proliferation, but did not show strong cell
death (Fig. 1). These results were somehow different
with the Cheong group study. However, these antitumor
effects were dependent on the different types of cancer
cells confirmed by other groups. Various types of malig-
nant cancers showed only a slowdown of cell growth ra-
ther than cell death, and the administration of only 2DG
had no significant effects in vivo [8, 34]. However, it is
clear that 2DG has a strong inhibition effect on cancer
cell growth.
2DG promotes these effects through decreased intra-
cellular ATP levels and ER stress by blocking glycolysis,
which leads to autophagy induction. In this study, we
found that increased autophagy with rapamycin or LC3B
overexpression strongly suppressed PC3 cell growth
(Fig. 5c and d). 2DG also increased autophagic flux at the
early phase and suppressed the growth of PC3 and LNCaP
cells (Fig. 1a and Additional file 1: Figure S1A). Overall,
2DG induced PC3 cell growth inhibition arose by autoph-
agy activation rather than autophagy inhibition.
However, we wondered why increased autophagic flux
at the early phase of 2DG treatment was gradually de-
creased at 48 h of treatment with 2DG although the
Fig. 5 Induction of autophagy suppresses cell growth and survival. Autophagic flux was regulated by chemical treatment or genetic modification
to prove the relationship between autophagic flux and cell growth. Autophagy was blocked with a various concentrations of CQ treatment or (b)
Beclin1-targeting shRNA. The level of Beclin1 expression was confirmed with western blotting for Beclin1 (Right panel). (c) Autophagy was induced
with rapamycin at the indicated concentrations. The level of LC3B expression was confirmed with western blotting for LC3B (Right panel). Data are
represented as the means ± SD, ***P < 0.001 versus 1 nM, ***P < 0.001 versus 10 nM, ***P < 0.001 versus 100 nM, ***P < 0.001 versus 1000 nM. (d) The
LC3B plasmid to overexpress LC3B was introduced into PC3 cells. Data are represented as the means ± SD. ***P < 0.001 versus 2DG, ***P < 0.001 versus
LC3B, ***P < 0.001 versus LC3B + 2DG. Cell growth rate was measured using an MTT assay (a and c) or cell counting (b and d). Autophagy
blocking did not show a synergistic effect with 2DG to regulate cell growth. However, autophagy induction suppressed cell growth, not
only with LC3B overexpression, but also with 2DG combination treatment, which showed a synergistic cell suppression effect
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AMPK signal, an autophagy inducing internal signaling
pathway, were constantly activated (Fig. 3).
Our results showed that the decreased mTOR/AKT
signaling pathway and increased AMPK signaling path-
way were continuously maintained by 2DG until the last
time points of sample preparation (Fig. 3b). AMPK is
well known as an intracellular energy sensor that has the
ability to detect the AMP:ATP ratio. In low levels of
ATP due to exercise or metabolic stress, AMPK is acti-
vated to inhibit energy consuming anabolic pathways
and promote energy producing catabolic pathways like
glucose uptake, glycolysis, and beta oxidation to increase
ATP levels. In addition, AMPK tightly regulates autoph-
agy through the inhibition of the mTOR signaling path-
way [35, 36].
One possibility for autophagy blocking by 2DG with
long-term treatment is lower levels of glucose and ATP
in the cytoplasm. ATP is a very important energy source
to maintain metabolic homeostasis, and is used as a
substrate to transfer energy for transducing signals by
kinase, as a material to make nucleic acids, and it
participates in biosynthetic processes [37, 38]. In
addition, ATP is a very critical for the process of au-
tophagy maturation [39]. Autophagy begins with pha-
gophore formation with a small double membrane,
and the end of the phagophore is elongated. After
then it engulfs the described substrate and encloses
the double membrane. This is called the autophagosome.
Many autophagy related proteins including ULK2, the au-
tophagy related (ATG) proteins, the focal adhesion kinase
family interacting protein FIP200, Beclin1, the human
phosphatidylinositol 3 kinase adaptor protein p150, the
class III phosphatidylinositol-3 kinase VPS34, and LC3
participate in this process. The autophagosome fuses with
the lysosome to construct the autolysosome that degrades
the autophagosome contained substrates to recycle bio-
materials [40]. ATP is required for these sequestrations by
autophagosome [41, 42]. ATP has a crucial role in main-
tenance of V-ATPase activity that produces lysosomal
acidification to optimize lysosomal hydrolases within the
lysosomal membrane. V-ATPase consists of ATP
hydrolysis-acting V1 and proton translocation-acting
V0. Lower levels of ATP due to limited glucose supply
promotes separation of these two components and
causes loss of V-ATPase activity, which inhibits au-
tophagic flux and blocks autophagy cargo degradation
by lysosomal proteases [43–45]. Similarly, long-term
treatment of 2DG prohibits glycolysis and sufficient
ATP synthesis, which reduces autolysosome conform-
ation and autophagic flux. This could partially explain
the inhibition of autophagic flux by 2DG. Because
ATP is synthesized not only by glycolysis, but also
beta oxidation in the mitochondria, blocking of gly-
colysis with 2DG did not perfectly inhibit ATP
synthesis. Supplements of glutamine via glutaminolysis
and pyruvates to the mitochondria could make ATP
[46]. So, in our experimental conditions, the reason
for inhibition of autophagic flux by depletion of ATP
with 2DG treatment is not enough.
Another possibility is a defense mechanism for sur-
vival in cells. Recent reports use the term "autophagic
cell death," which means unlimited autophagy activation.
It leads to cell death because autophagy uptakes and de-
grades not only the properly eliminated proteins or or-
ganelles, but also the normal intracellular components
that work well in the cell [28]. Some groups reported the
possibility of clinical cancer therapy using autophagy in-
ducers that promote autophagic cell death in cancer cells
[28, 47, 48]. In cancer cells, this autophagic cell death is
thoroughly prevented for survival, so does 2DG treated
PC3 cells. In our results, blocking of autophagy through
chemical or genetic inhibitory manipulation did not have
significant anticancer effects compared with normal cul-
ture conditions. Knockdown of an autophagy related
gene showed only increased autophagic flux blocking
and little change in cell cycle related gene expression
(Fig. 4). In addition, inhibition of autophagic flux by CQ
or shRNA showed no remarkable difference in PC3 cell
growth (Fig. 5a and b). In contrast, overactivation of au-
tophagy by both rapamycin and overexpression of LC3B
significantly suppressed cancer cell growth, and add-
itional treatment of 2DG into overactivated autophagy
conditions strongly decreased PC3 cell viability (Fig. 5c
and d). In LNCaP cells, the effect of cell growth inhib-
ition by rapamycin was more intense than in PC3 cells
(Additional file 3: Figure S3B).
Although cell death through autophagy was very
dependent on cell type and culture environments, recent
reports demonstrated that increased autophagic flux has
strong anticancer effects [24, 49, 50]. Zhao et al. report
that acetylated Foxo1 interacted with Atg7 and E1-like
protein and the oxidative stress increased autophagic
flux, leading to cell death. Similar to our results, exces-
sive autophagy activation by increased intracellular ER
stress and ROS levels induced cell death [50]. Taken to-
gether, metabolic stress causes autophagy activation and
leads to cell death. However, the detailed mechanism for
the regulation of autophagic flux in cancer cell survival
is not clear and needs to be studied further [27, 28].
Conclusion
2DG treatment inhibits PC3 cell growth and differen-
tially regulates autophagic flux time dependently. Short-
term treatment of 2DG strongly induces autophagic flux,
which causes cell growth inhibition, but long-term treat-
ment blocks the autophagic flux needed for PC3 cell sur-
vival and maintenance. Although these findings need
more detailed molecular and physiological mechanisms
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for autophagy regulation, these results are important evi-
dence for exploring new therapeutic agents for cancer
by inducing autophagy and maintaining excessive au-
tophagic flux.
Additional files
Additional file 1: Figure S1. 2-deoxyglucose regulates LNCaP prostate
cancer cell growth, autophagy and cell cycle. LNCap cells were incubated
with different concentrations of 2-deoxyglucose (2DG). (A) Cell growth
rate was measured using MTT assay at the indicated time points for 3 days.
Data are represented as means ± SD. ***P < 0.001, control versus 5 mM 2DG;
***P < 0.001, control versus 10 mM 2DG; ***P < 0.001, control versus 20 mM
2DG. (B) After 2DG treatment for 48 h, autophagy levels were detected
using western blotting analysis. p62 was used as an autophagy substrate
and LC3B showed autophagy levels. (C) LNCaP cells were treated
with 2DG for a short time (6 h) or long time (48 h). CQ was used as
an autophagy inhibitor at a final concentration of 20 μM for 2 h.
Rapamycin was used as an autophagy inducer at 100 nM for 6 h.
Expression levels of cell cycle-related genes were observed using
western blotting analysis. Long-term exposure to 2DG enhances cell
cycle arrest. (TIFF 2456 kb)
Additional file 2: Figure S2. Autophagic flux is differentially regulated
by exposure time to 2DG. 2DG was administered to LNCaP cells, with CQ
or alone, to confirm autophagic flux. (A) Protein levels of p62 and LC3B
in 2DG-containing culture medium for the indicated time followed by
CQ or no further treatment were observed with western blotting. (B)
Autophagic flux calculated by the accumulated amount of LC3B with
treatment of CQ for 2 h. Data are represented as the means ± SD. ***P <
0.001 for both culture conditions. (C) The changes in intracellular signaling
pathway related autophagy regulation were verified for each condition.
Phosphorylated level of mTOR was checked for whether the inhibitory
signal of autophagy was induced. The AMPK signaling pathway was
confirmed as an autophagy activating condition. (TIFF 3616 kb)
Additional file 3: Figure S3. Induction of autophagy suppresses cell
growth and survival. Autophagic flux was regulated by chemical
treatment to prove the relationship between autophagic flux and cell
growth. (A) Autophagy was blocked with various concentrations of CQ
treatment (B) Autophagy was induced with rapamycin at the indicated
concentrations. Data are represented as the means ± SD, ***P < 0.001
versus 1 nM, ***P < 0.001 versus 10 nM, ***P < 0.001 versus 100 nM,
***P < 0.001 versus 1000 nM. Cell growth rate was measured using an
MTT assay. Autophagy blocking did not show a synergistic effect with
2DG to regulate cell growth. However, autophagy induction significantly
suppressed cell growth. (TIFF 1295 kb)
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